The US Food and Drug Administration has made unannounced inspections the operational norm for Indian facilities that supply American patients. In the fiscal year ended 31 March 2026, 87% of its audits in India arrived without prior notice, up from 47% the year before. The same manufacturing base that serves the Indian market continues to operate under a system whose day-to-day capacity to impose comparable scrutiny remains structurally limited.
The disparity is not rhetorical. It is measurable in inspector strength, inspection frequency, enforcement architecture, and the persistence of quality failures that reach Indian patients.





